Immuneering (NASDAQ:IMRX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Needham & Company LLC in a report issued on Thursday,Benzinga reports. They presently have a $9.00 price objective on the stock. Needham & Company LLC’s …
Needham & Company LLC Reaffirms Buy Rating for Immuneering (NASDAQ:IMRX)
